Multiple myeloma patients treated with BCMA-directed CAR T-cell therapy have high response rate
Published: 7 Dec 2019
Views: 978
Prof Deepu Madduri - Mount Sinai, New York, USA
Prof Deepu Madduri presents data from the CARTITUDE-1 study during a press conference at the ASH 2019 meeting.
The study evaluated the response rate of JNJ-4528, a CAR-T Cell Therapy directed against B-Cell maturation antigen (BCMA), in multiple myeloma patients.
Read more about the study here.
Watch our interview with Prof Deepu Madduri here.
- Categories:
- Haematology oncology
- Antibodies & immunotherapy
Related Videos
Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma
Dr Noemí Puig - Hospital Universitario de Salamanca, Salamanca, Spain
25 Sep 2020
Managing multiple myeloma in a COVID-19 world
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France
25 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
Evaluating the impact of daratumumab for the treatment of multiple myeloma accor...
Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA
10 Jul 2020
MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD res...
Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA
9 Jul 2020
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with r...
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
30 Jun 2020
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patient...
Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy
26 Jun 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
26 Jun 2020
